Kwality Pharmaceuticals MD, chairman, board of directors and AGM
NSE: KPLBSE: 539997Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹3,618.30.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹3,661 Cr1,235th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 45.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 11.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 27.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 25.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 38,71643.8% delivered
Kwality Pharmaceuticals board of directors
At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- Managing directorRAMESH KUMAR
- Company Secretary and Compliance OfficerGURPREET KAUR
10 directors5 independent5 executive
- RAMESH KUMAR · Managing directorExecutive · joined May 1983 · reappointed Jan 2026 · 1 listed board
- AJAY KUMAR ARORAExecutive · joined Aug 1995 · reappointed Jan 2026 · 1 listed board
- ADITYA ARORAExecutive · joined Oct 2015 · reappointed Sep 2021 · 1 listed board · 1 committee seat
- GEETA ARORAExecutive · joined Oct 2010 · reappointed Jan 2026 · 1 listed board · 1 committee seat
- ANJU ARORAExecutive · joined Oct 2010 · reappointed Jan 2026 · 1 listed board · 1 committee seat
- VINOD KUMAR SHARMAIndependent · joined Jul 2025 · 11 months as independent · 1 listed board · 1 as independent · 1 committee seat
- PREETMOHINDER SINGH BEDIIndependent · joined Jan 2026 · 6 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- BHAVESH MAHAJANIndependent · joined Jan 2026 · 5 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- PRASHANTH VELLANKIIndependent · joined Mar 2023 · 39 months as independent · 1 listed board · 1 as independent
- SWANITH KAPOORIndependent · joined Jun 2026 · 0 months as independent · 1 listed board · 1 as independent
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
4 directors who left
- KARTIK KAPUR, left 2 Jun 2026: Others
- PANKAJ TAKKAR, left 31 Jan 2026: Tenure Completion
- RAVI SHANKER SINGH, left 31 Jan 2026: Tenure Completion
- KIRAN KUMAR VERMA, left 26 Jul 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 2 Jun 20268 of 10 present3 independent · 13 days in between
- 19 May 20268 of 10 present3 independent · 48 days in between
- 31 Mar 20268 of 10 present3 independent · 37 days in between
- 21 Feb 20267 of 10 present2 independent · 8 days in between
3 earlier meetings
- 12 Feb 20268 of 10 present3 independent · 14 days in between
- 28 Jan 20268 of 12 present3 independent · 26 days in between
- 1 Jan 20267 of 11 present2 independent
Audit Committee
Chair BHAVESH MAHAJAN
ADITYA ARORA, VINOD KUMAR SHARMA
- 19 May 20263 of 3 present2 independent · 18 days in between
- 30 Apr 20263 of 3 present2 independent · 76 days in between
- 12 Feb 20263 of 3 present2 independent
Nomination and remuneration committee
Chair VINOD KUMAR SHARMA
BHAVESH MAHAJAN, PREETMOHINDER SINGH BEDI
- 30 Apr 20263 of 3 present3 independent · 99 days in between
- 20 Jan 20263 of 3 present3 independent
Stakeholders Relationship Committee
Chair PREETMOHINDER SINGH BEDI
GEETA ARORA, ANJU ARORA
- 30 Mar 20263 of 3 present1 independent
Corporate Social Responsibility Committee
Chair GEETA ARORA
ADITYA ARORA, BHAVESH MAHAJAN
- 30 Mar 20263 of 3 present1 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- VIJAY MEHRA & CO.Peer-review certificate valid to Aug 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Kwality Pharmaceuticals AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Kwality Pharmaceuticals dividend history
Annual general meeting, 31 Aug 2026
16,570 shareholders on the register on 24 Aug 2026; present: 6 promoters and 28 others; votes counted by RISHI MITTAL / RISHI MITTAL & ASSOCIATES.The company's voting result (opens in a new tab)
To receive, consider and adopt: (i) the Audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2026, together with Reports of the Board of Directors and Auditors' thereon. (ii)the Audited Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2026 and the Report of the Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 45.10% · promoters 76.58% · institutions 55.72% · other public 2.41%
To appoint a Director in place of Mr. ADITYA ARORA (DIN: 07320410), liable to retire by rotation in terms of Section 152(6) of the Companies Act, 2013 and being eligible, offers himself for reappointment.MoreLess
OrdinaryPromoters have an interest in it99.97% for0.03% againstAgainst: promoters 0.00% · institutions 0.70% · other public 0.01%
Turnout: all 45.10% · promoters 76.58% · institutions 55.72% · other public 2.41%
To appoint a Director in place of Mrs. ANJU ARORA (DIN : 03155641), liable to retire by rotation in terms of Section 152(6) of the Companies Act,2013 and being eligible, offers herself for re-appointment.MoreLess
OrdinaryPromoters have an interest in it100.00% for0.00% againstAgainst: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 45.10% · promoters 76.58% · institutions 55.72% · other public 2.41%
- APPOINTMENT OF MR. SWANITH KAPOOR (DIN: 11662482) AS AN INDEPENDENT DIRECTOR OF THE COMPANYSpecial99.96% for0.04% against
Against: promoters 0.00% · institutions 0.79% · other public 0.01%
Turnout: all 45.10% · promoters 76.58% · institutions 55.72% · other public 2.41%
- RE-APPOINTMENT OF MR. ADITYA ARORA (DIN: 07320410), AS WHOLE TIME DIRECTOR OF THE COMPANY AND APPROVAL OF PAYMENT OF REMUNERATIONSpecialPromoters have an interest in it99.97% for0.03% against
Against: promoters 0.00% · institutions 0.70% · other public 0.01%
Turnout: all 45.10% · promoters 76.58% · institutions 55.72% · other public 2.41%
- RATIFICATION OF COST AUDITORS REMUNERATIONOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 45.10% · promoters 76.58% · institutions 55.72% · other public 2.41%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How mutual funds voted
Fund houses must disclose how they vote at every meeting of a company they hold.
Mutual fund votes, meeting of 28 Mar 2026, 2 fund houses
To approve appointment of Mr. Bhavesh Mahajan (DIN: 09614108) as an Independent Director of the Company, not liable to retire by rotation, for a term of five consecutive years commencing from January 28, 2026 to January 27, 2031 (both days inclusive).MoreLess
2 for0 againstTo approve appointment of Mr. Preetmohinder Singh Bedi (DIN:11452004) as an Independent Director of the Company, not liable to retire by rotation, for a term of five consecutive years commencing from January 01, 2026 to December 31, 2030 (both days inclusive).MoreLess
2 for0 against
Each fund house counted once, from its own disclosure; the reasons are its own words.
Tax disputes
Reported in the filing for the quarter to Jun 2026.
- Tax disputeAdditional Commissioner, CGST Commissionerate, JalandharSince 29 Nov 2024The Company had filed an appeal before the appropriate appellate authority under CGST Act, 2017 challenging the said order and the proceedings are pending as on the date of this report.At the filing before: The company had received order for Erroneous Refund of IGST (FY 2017–18 to 2022–23) under Section 74(9) of the CGST Act, 2017 read with Section 20 of the IGST Act, 2017, raising demand and penalty.
- Tax disputeCentral Excise &CGST Commissionerate, JalandharSince 3 Aug 2024
The company had filed a civil writ petition in the Punjab and Haryana high court against the said show cause notice. Hon’ble Punjab and Haryana high court has stayed the passing of adjudication order in pursuance to the show cause notice and the show cause notice is thus under litigation and remains pending as on the reporting date.MoreLess
At the filing before: The company had received Show Cause Notice Alleging Wrongful Availment of ITC (FY 2017–18 to 2022–23) under Section 74 & 122 of the Central Goods and Services Tax Act, 2017 raising demand and penalty. - Tax disputeAssistant Commissioner, CGST AmritsarSince 30 Dec 2024The Company had filed an appeal before the appropriate appellate authority under the GST Commissionerate and the proceedings are pending as on the date of this report.At the filing before: The company had received orders in Form DRC-07 for ITC Disputes from the GST Department under Section 74 of the CGST Act, 2017 for FY 2017–18, FY 2019–20 and FY 2020–21 raising demand and penalty.
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- No
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.